B16 melanoma cells were engineered to overexpress IFNα2, α4, α5, α6, or α9, but only IFNα2- and α9-expressing tumors were effectively controlled in an adaptive-immunity dependent manner (247). This evidence concerns the gene IFNA2 and melanoma.